
- Pharmaceutical Commerce - November/December 2015
TMS Health steps more deeply into specialty services with acquisition of inVentiv's Patient Access Solutions (iPAS)
Xerox subsidiary expands its call-center operations to include specialty reimbursement services
At the CBI Hub Models Conference (San Diego, Sept. 29-30), Valerie Sullivan, managing director of the newly acquired business unit, had a simple comment on the changed ownership: "People who knew iPAS as part of inVentiv will recognize the same services and level of quality as part of Xerox. We're excited at the direction we're going in."
Under the acquisition, announced at the beginning of September, iPAS will become a business unit of TMS Health, a Xerox Company, which is one of the largest providers in the US of call-center and inside-sales support to life sciences companies. iPAS itself is primarily a call center, specializing in handling patient-access and reimbursement services for specialty pharmaceutical marketers. As part of “an ongoing relationship” with inVentiv, says Xerox, iPAS will continue to provide its services to clients of inVentiv’s Contract Commercial Organization.
iPAS has been one of a growing number of organizations providing what are commonly called hub services to specialty pharma marketers; the specialty products usually stand out because of their high cost and complex methods of arranging reimbursement with payers. Some hub providers (like iPAS) concentrate on the reimbursement and prior-authorization requirements; others add in ongoing patient counseling or care coordination with other healthcare providers and pharmacies.
Articles in this issue
almost 10 years ago
Who's the best in business-process outsourcing?almost 10 years ago
PDI chooses Veeva's Network Customer Master solution for MDM managementalmost 10 years ago
Zephyr Health introduces a new IT tool for product life-cycle managementalmost 10 years ago
Transparency-reporting trends in Europealmost 10 years ago
For better patient data in pharma, think CUPIDalmost 10 years ago
GDUFA Fee Relief For Small Businessesalmost 10 years ago
Dissecting the speed-to-therapy questionalmost 10 years ago
AmerisourceBergen defines its path forward in traceabilityalmost 10 years ago
Getting products to market fast with the 3PL Title Modelalmost 10 years ago
Cell 'banking' business will grow 16%+ annually, to $9.87 billion in 2022Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.